	US 12,441,802 B2
	Anti-B7-H3 antibody and methods of use thereof
Ellen Collarini, Oakland, CA (US); Shelley Izquierdo, Berkeley, CA (US); Christel Iffland, Arlington, MA (US); and William Don Harriman, Alameda, CA (US)
Assigned to CRYSTAL BIOSCIENCE INC., Emeryville, CA (US)
Appl. No. 17/612,959
Filed by Crystal Bioscience Inc., San Diego, CA (US)
PCT Filed Jun. 26, 2020, PCT No. PCT/US2020/039931 § 371(c)(1), (2) Date Nov. 19, 2021, PCT Pub. No. WO2021/003075, PCT Pub. Date Jan. 7, 2021.
Claims priority of provisional application 62/870,549, filed on Jul. 3, 2019.
Prior Publication US 2022/0298246 A1, Sep. 22, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 47/00 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

21 Claims

1. An antibody that binds to B7-H3, wherein the antibody comprises:

a variable domain comprising:

i. heavy chain CDR1, CDR2 and CDR3 regions that are identical to the heavy chain CDR1, CDR2 and CDR3 regions of SEQ ID NO: 39; and

ii. light chain CDR1, CDR2 and CDR3 regions that are identical to the light chain CDR1, CDR2 and CDR3 regions of SEQ ID NO: 93,

wherein SEQ ID NOS: 39 and 93 are the respective heavy and light chains of antibody 40633p1.1.G7.